Restricted accessResearch articleFirst published online 2024-07
S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
Imatinib (IM), a breakthrough in chronic myeloid leukemia (CML) treatment, is accompanied by discontinuation challenges owing to drug intolerance. Although BCR-ABL1 mutation is a key cause of CML resistance, understanding mechanisms independent of BCR-ABL1 is also important. This study investigated the sphingosine-1-phosphate (S1P) signaling-associated genes (SphK1 and S1PRs) and their role in BCR-ABL1-independent resistant CML, an area currently lacking investigation. Through comprehensive transcriptomic analysis of IM-sensitive and IM-resistant CML groups, we identified the differentially expressed genes and found a notable upregulation of SphK1, S1PR2, and S1PR5 in IM-resistant CML. Functional annotation revealed their roles in critical cellular processes such as proliferation and GPCR activity. Their network analysis uncovered significant clusters, emphasizing the interconnectedness of the S1P signaling genes. Further, we identified interactors such as BIRC3, TRAF6, and SRC genes, with potential implications for IM resistance. Additionally, receiver operator characteristic curve analysis suggested these genes’ potential as biomarkers for predicting IM resistance. Network pharmacology analysis identified six herbal compounds—ampelopsin, ellagic acid, colchicine, epigallocatechin-3-gallate, cucurbitacin B, and evodin—as potential drug candidates targeting the S1P signaling genes. In summary, this study contributes to efforts to better understand the molecular mechanisms underlying BCR-ABL1-independent CML resistance. Moreover, the S1P signaling genes are promising therapeutic targets and plausible new innovation avenues to combat IM resistance in cancer clinical care in the future.
Get full access to this article
View all access options for this article.
References
1.
AliM, WaniSUD, SalahuddinM, et al.Recent advance of herbal medicines in cancer- a molecular approach. Heliyon, 2023; 9(2):e13684; doi: 10.1016/j.heliyon.2023.e13684
2.
AlmejúnMB, BorgeM, ColadoA, et al.Sphingosine kinase 1 participates in the activation, proliferation, and survival of chronic lymphocytic leukemia cells. Haematologica, 2017; 102(7):e257–e260; doi: 10.3324/haematol.2017.167353
3.
AlshakerH, KrellJ, FramptonAE, et al.Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway. Breast Cancer Res, 2014; 16(5):426; doi: 10.1186/s13058-014-0426-6
4.
AlvesR, GonçalvesAC, RutellaS, et al.Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—From molecular mechanisms to clinical relevance. Cancers (Basel), 2021; 13(19):4820; doi: 10.3390/cancers13194820
5.
AsifW, QureshiHK, IqbalA, et al.On the complexity of average path length for biological networks and patterns. Int J Biomath, 2014; 07(04):1450038; doi: 10.1142/S1793524514500387
6.
AssenovY, RamírezF, SchelhornS-E, et al.Computing topological parameters of biological networks. Bioinformatics, 2008; 24(2):282–284; doi: 10.1093/bioinformatics/btm554
7.
BaderGD, HogueCW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics, 2003; 4:2.
8.
BaranY, SalasA, SenkalCE, et al.Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem, 2007; 282(15):10922–10934; doi: 10.1074/jbc.M610157200
9.
BonhoureE, PchejetskiD, AoualiN, et al.Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting shingosine kinase-1. Leukemia, 2006; 20(1):95–102; doi: 10.1038/sj.leu.2404023
10.
CaiY, FangX, HeC, et al.Cucurbitacins: A systematic review of the phytochemistry and anticancer activity. Am J Chin Med, 2015; 43(7):1331–1350; doi: 10.1142/S0192415X15500755
11.
ChenY, LiangJ, LiangX, et al.Limonin induces apoptosis of HL‐60 cells by inhibiting NQO1 activity. Food Sci Nutr, 2021; 9(4):1860–1869; doi: 10.1002/fsn3.2109
12.
ChenZ, VallegaKA, ChenH, et al.The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition. Pharmacol Res, 2022b;175:105998; doi: 10.1016/j.phrs.2021.105998
13.
ChenH, WangJ, ZhangC, et al.Sphingosine 1-phosphate receptor, a new therapeutic direction in different diseases. Biomed Pharmacother, 2022a;153:113341; doi: 10.1016/j.biopha.2022.113341
14.
ChinC-H, ChenS-H, WuH-H, et al.cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst Biol, 2014; 8(Suppl 4):S11; doi: 10.1186/1752-0509-8-S4-S11
15.
ClarkeG, CollinsRA, LeavittBR, et al.A one-hit model of cell death in inherited neuronal degenerations. Nature, 2000; 406(6792):195–199; doi: 10.1038/35018098
16.
DuboisS, ViaillyP-J, MareschalS, et al.Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: A LYSA Study. Clin Cancer Res, 2016; 22(12):2919–2928; doi: 10.1158/1078-0432.CCR-15-2305
17.
FuD, LiY, LiJ, et al.The effect of S1P receptor signaling pathway on the survival and drug resistance in multiple myeloma cells. Mol Cell Biochem, 2017; 424(1-2):185–193; doi: 10.1007/s11010-016-2854-3
18.
FuldaS. Inhibitor of Apoptosis (IAP) Proteins in hematological malignancies: Molecular mechanisms and therapeutic opportunities. Leukemia, 2014; 28(7):1414–1422; doi: 10.1038/leu.2014.56
19.
KimD, LangmeadB, SalzbergSL. HISAT: A fast spliced aligner with low memory requirements. Nat Methods, 2015; 12(4):357–360; doi: 10.1038/nmeth.3317
20.
KotlyarM, PastrelloC, PivettaF, et al.In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods, 2014; 12(1):79–84.
21.
KoutrouliM, KaratzasE, Paez-EspinoD, et al.A guide to conquer the biological network era using graph theory. Front Bioeng Biotechnol, 2020; 8:34; doi: 10.3389/fbioe.2020.00034
22.
LeungYY, Yao HuiLL, KrausVB. Colchicine—Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum, 2015; 45(3):341–350; doi: 10.1016/j.semarthrit.2015.06.013
23.
LiY, ZengP, XiaoJ, et al.Modulation of energy metabolism to overcome drug resistance in chronic myeloid leukemia cells through induction of autophagy. Cell Death Discov, 2022; 8(1):212; doi: 10.1038/s41420-022-00991-w
24.
LiaoY, SmythGK, ShiW. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics, 2014; 30(7):923–930; doi: 10.1093/bioinformatics/btt656
25.
LuoH, VongCT, ChenH, et al.Naturally occurring anti-cancer compounds: Shining from Chinese herbal medicine. Chin Med, 2019; 14(1):48; doi: 10.1186/s13020-019-0270-9
26.
MaceykaM, HarikumarKB, MilstienS, et al.Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol, 2012; 22(1):50–60; doi: 10.1016/j.tcb.2011.09.003
27.
MarfeG, Di StefanoC, GambacurtaA, et al.Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Exp Hematol, 2011; 39(6):653–665.e6; doi: 10.1016/j.exphem.2011.02.013
28.
MatulaK, Collie-DuguidE, MurrayG, et al.Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer, 2015; 15(1):762; doi: 10.1186/s12885-015-1718-7
29.
Meenakshi SundaramDN, JiangX, BrandweinJM, et al.Current outlook on drug resistance in Chronic Myeloid Leukemia (CML) and potential therapeutic options. Drug Discov Today, 2019; 24(7):1355–1369; doi: 10.1016/j.drudis.2019.05.007
30.
MuppidiJR, SchmitzR, GreenJA, et al.Loss of signalling via gα13 in germinal centre b-cell-derived lymphoma. Nature, 2014; 516(7530):254–258; doi: 10.1038/nature13765
31.
OhotskiJ, RosenH, BittmanR, PyneS, PyneNJ. Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: The role of sphingosine 1-phosphate receptor-4. Cell Signal, 2014; 26(5):1040–1047.
32.
PatelAB, O’HareT, DeiningerMW. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am, 2017; 31(4):589–612; doi: 10.1016/j.hoc.2017.04.007
33.
PchejetskiD, GolzioM, BonhoureE, et al.Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res, 2005; 65(24):11667–11675.
34.
PowellJA, LewisAC, ZhuW, et al.Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood, 2017; 129(6):771–782; doi: 10.1182/blood-2016-06-720433
35.
ProiaRL, HlaT. Emerging biology of sphingosine-1-phosphate: Its role in pathogenesis and therapy. J Clin Invest, 2015; 125(4):1379–1387; doi: 10.1172/JCI76369
36.
PyneS, EdwardsJ, OhotskiJ, et al.Sphingosine 1-phosphate receptors and sphingosine kinase 1: Novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers. Front Oncol, 2012; 2:168; doi: 10.3389/fonc.2012.00168
37.
PyneNJ, PyneS. Recent advances in the role of sphingosine 1‐phosphate in cancer. FEBS Lett, 2020; 594(22):3583–3601; doi: 10.1002/1873-3468.13933
38.
QianF, WeiD, ZhangQ, et al.Modulation of P-glycoprotein function and reversal of multidrug resistance by (–)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother, 2005; 59(3):64–69; doi: 10.1016/j.biopha.2005.01.002
39.
RenX, SuC. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma. Mol Med Rep, 2020; 22(3):2183–2190; doi: 10.3892/mmr.2020.11295
40.
RitchieME, PhipsonB, WuD, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 2015; 43(7):e47–e47; doi: 10.1093/nar/gkv007
41.
RosaR, MarcianoR, MalapelleU, et al.Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res, 2013; 19(1):138–147; doi: 10.1158/1078-0432.CCR-12-1050
42.
SalasA, PonnusamyS, SenkalCE, et al.Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood, 2011; 117(22):5941–5952; doi: 10.1182/blood-2010-08-300772
43.
Sancho-AlonsoM, ArenasYM, Izquierdo-AltarejosP, et al.Enhanced activation of the S1PR2-IL-1β-Src-BDNF-TrkB pathway mediates neuroinflammation in the hippocampus and cognitive impairment in hyperammonemic rats. Int J Mol Sci, 2023; 24(24):17251; doi: 10.3390/ijms242417251
44.
ShannonP, MarkielA, OzierO, et al.Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003; 13(11):2498–2504; doi: 10.1101/gr.1239303
45.
ShimonoJ, MiyoshiH, YoshidaN, et al.Analysis of GNA13 protein in follicular lymphoma and its association with poor prognosis. Am J Surg Pathol, 2018; 42(11):1466–1471.
46.
SongL, XiongH, LiJ, et al.Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-kB pathway in human non–small cell lung cancer. Clin Cancer Res, 2011; 17(7):1839–1849.
47.
StellingA, HashwahH, BertramK, et al.The tumor supressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood, 2018; 131(20):2235–2246; doi: 10.1182/blood-2017-10-810630
48.
SzklarczykD, KirschR, KoutrouliM, et al.The STRING database in 2023: Protein–protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res, 2023; 51(D1):D638–D646; doi: 10.1093/nar/gkac1000
49.
TsuchidaJ, NagahashiM, TakabeK, et al.Clinical impact of sphingosine-1-phosphate in breast cancer. Mediators Inflamm, 2017; 2017:2076239–2076239; doi: 10.1155/2017/2076239
50.
TuliHS, SakK, GargVK, et al.Ampelopsin targets in cellular processes of cancer: Recent trends and advances. Toxicol Rep, 2022; 9:1614–1623; doi: 10.1016/j.toxrep.2022.07.013
51.
VarfolomeevE, WaysonSM, DixitVM, et al.The inhibitor of apoptosis protein fusion C-IAP2·MALT1 stimulates NF-κB activation independently of TRAF1 AND TRAF2. J Biol Chem, 2006; 281(39):29022–29029; doi: 10.1074/jbc.M605116200
52.
WangY, ShenY, SunX, et al.Prognostic roles of the expression of sphingosine-1-phosphate metabolism enzymes in non-small cell lung cancer. Transl Lung Cancer Res, 2019; 8(5):674–681; doi: 10.21037/tlcr.2019.10.04
53.
XiongH, WangJ, GuanH, et al.SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating bim via stimulating Akt/FoxO3a signaling. Oncol Rep, 2014; 32(4):1369–1373; doi: 10.3892/or.2014.3391
54.
XuK, BezakovaI, BunimovichL, et al.Path lengths in protein–protein interaction networks and biological complexity. Proteomics, 2011; 11(10):1857–1867; doi: 10.1002/pmic.201000684
55.
XuY, WangZ, ZhangL, et al.Differentiation of imatinib-resistant chronic myeloid leukemia cells with BCR-ABL-T315I mutation induced by jiyuan oridonin a. J Cancer, 2023; 14(7):1182–1194; doi: 10.7150/jca.83219
56.
YuM, ZhangK, WangS, et al.Increased SPHK1 and HAS2 expressions correlate to poor prognosis in pancreatic cancer. bellini mi. ed. Biomed Res Int, 2021; 2021:8861766; doi: 10.1155/2021/8861766
57.
ZakerE, NouriN, SorkhizadehS, et al.The importance of personalized medicine in chronic myeloid leukemia management: A narrative review. Egypt J Med Hum Genet, 2023; 24(1):31; doi: 10.1186/s43042-023-00411-3
58.
ZhangY, CuiS, WanS, et al.Increased S1P induces S1PR2 internalization to blunt the sensitivity of colorectal cancer to 5-fluorouracil via promoting intracellular uracil generation. Acta Pharmacol Sin, 2021; 42(3):460–469; doi: 10.1038/s41401-020-0460-0
59.
ZhangH-M, ZhaoL, LiH, et al.Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med, 2014; 11(2):92–100.
60.
ZhangC, ZhouC, XuJ, et al.Increased sphingosine kinase 1 expression is associated with poor prognosis in human solid tumors: A meta-analysis. mathioudakis AG. ed. Dis Markers, 2022; 2022:8443932–8443912; doi: 10.1155/2022/8443932
61.
ZhaoX, LiuZ-P. Analysis of topological parameters of complex disease genes reveals the importance of location in a biomolecular network. Genes (Basel), 2019; 10(2):143; doi: 10.3390/genes10020143
62.
ZhengX, LiW, RenL, et al.The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy. Pharmacol Ther, 2019; 195:85–99; doi: 10.1016/j.pharmthera.2018.10.011
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
